CO2022011467A2 - Polipéptidos, composiciones y su uso para tratar o limitar el desarrollo de una infección - Google Patents
Polipéptidos, composiciones y su uso para tratar o limitar el desarrollo de una infecciónInfo
- Publication number
- CO2022011467A2 CO2022011467A2 CONC2022/0011467A CO2022011467A CO2022011467A2 CO 2022011467 A2 CO2022011467 A2 CO 2022011467A2 CO 2022011467 A CO2022011467 A CO 2022011467A CO 2022011467 A2 CO2022011467 A2 CO 2022011467A2
- Authority
- CO
- Colombia
- Prior art keywords
- polypeptides
- infection
- treat
- development
- limit
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062977036P | 2020-02-14 | 2020-02-14 | |
| US202063046159P | 2020-06-30 | 2020-06-30 | |
| US202063064235P | 2020-08-11 | 2020-08-11 | |
| PCT/US2021/017799 WO2021163438A1 (en) | 2020-02-14 | 2021-02-12 | Polypeptides, compositions, and their use to treat or limit development of an infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022011467A2 true CO2022011467A2 (es) | 2022-10-31 |
Family
ID=74873805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0011467A CO2022011467A2 (es) | 2020-02-14 | 2022-08-16 | Polipéptidos, composiciones y su uso para tratar o limitar el desarrollo de una infección |
Country Status (13)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
| US11192940B2 (en) | 2020-04-10 | 2021-12-07 | Adagio Therapeutics, Inc. | Compounds specific to coronavirus S protein and uses thereof |
| US20220016268A1 (en) * | 2020-07-17 | 2022-01-20 | Tonix Pharmaceuticals Holding Corp. | Skin-based testing for detection of cell-mediated immune responses to sars-cov-2 |
| MX2023007574A (es) | 2020-12-22 | 2023-09-29 | CureVac SE | "vacuna de arn contra variantes de sars-cov-2. |
| US20220324918A1 (en) * | 2021-03-30 | 2022-10-13 | Regents Of The University Of Minnesota | SARS-CoV-2 SPIKE ECTODOMAIN POLYPEPTIDES AND COMPOSITIONS AND METHODS THEREOF |
| WO2023034991A1 (en) * | 2021-09-02 | 2023-03-09 | Kansas State University Research Foundation | Mrna vaccine formulations and methods of using the same |
| WO2023039540A2 (en) * | 2021-09-10 | 2023-03-16 | Jacobs Technion-Cornell Institute | Compositions and methods for determining humoral immune responses against seasonal coronaviruses and predicting efficiency of sars-cov-2 spike targeting, covid-19 disease severity, and providing interventions |
| KR102621026B1 (ko) * | 2021-10-15 | 2024-01-09 | 에스케이바이오사이언스(주) | 단백질의 정제방법 |
| KR102527221B1 (ko) * | 2021-10-15 | 2023-05-02 | 에스케이바이오사이언스 주식회사 | 단백질의 정제방법 |
| KR102524839B1 (ko) * | 2021-11-04 | 2023-04-25 | 에스케이바이오사이언스(주) | 사스-코로나바이러스-2 감염증 예방 또는 치료용 백신 조성물 |
| US20250000968A1 (en) * | 2021-11-12 | 2025-01-02 | The United States of America, as represented by the Secretary,Department of Health and Human Service | Sars-cov-2 spike fused to a hepatitis b surface antigen |
| WO2023122257A2 (en) * | 2021-12-22 | 2023-06-29 | La Jolla Institute For Immunology | Coronavirus spike glycoprotein with improved expression and stability |
| CN114656571B (zh) * | 2022-02-18 | 2024-07-16 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | 一种四价SARS-CoV-2嵌合纳米颗粒疫苗及其制备方法与应用 |
| US20240207389A1 (en) * | 2022-04-27 | 2024-06-27 | Northwestern University | Methods for improving covid vaccine immunogenicity |
| KR102689037B1 (ko) * | 2022-07-12 | 2024-07-30 | 에스케이바이오사이언스 주식회사 | SARS-CoV-2 백신 부스터 조성물 |
| KR20250084945A (ko) * | 2022-10-05 | 2025-06-11 | 유니버시티 오브 워싱턴 | 범사르베코바이러스 나노입자 백신 |
| WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
| WO2024218715A1 (en) | 2023-04-19 | 2024-10-24 | Btl Healthcare Technologies A.S. | Culture media based on protein hydrolysate and a process for preparing thereof |
| US12668774B2 (en) | 2023-10-12 | 2026-06-30 | Btl Healthcare Technologies A.S. | Product, system and method of cell cultivation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009016639A2 (en) * | 2007-08-02 | 2009-02-05 | Biondvax Pharmaceuticals Ltd. | Multimeric multiepitope influenza vaccines |
| US10248758B2 (en) * | 2013-02-07 | 2019-04-02 | University Of Washington Through Its Center For Commercialization | Self-assembling protein nanostructures |
| WO2015080973A1 (en) * | 2013-11-26 | 2015-06-04 | Baylor College Of Medicine | A novel sars immunogenic composition |
| US9630994B2 (en) * | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
| WO2017046801A1 (en) * | 2015-09-17 | 2017-03-23 | Ramot At Tel-Aviv University Ltd. | Coronaviruses epitope-based vaccines |
| WO2018175560A1 (en) * | 2017-03-22 | 2018-09-27 | The Scripps Research Institute | Nanoparticle immunogens to elicit responses against the influenza receptor binding site on the hemagglutinin head domain |
| EP3606942B1 (en) * | 2017-04-04 | 2025-06-11 | University of Washington | Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use |
| CN112088014B (zh) * | 2018-02-28 | 2026-03-24 | 华盛顿大学 | 自组装纳米结构疫苗 |
-
2021
- 2021-02-12 EP EP21711980.9A patent/EP4103230A1/en active Pending
- 2021-02-12 CN CN202180028727.9A patent/CN116096404A/zh active Pending
- 2021-02-12 JP JP2022548783A patent/JP7897796B2/ja active Active
- 2021-02-12 MX MX2022009860A patent/MX2022009860A/es unknown
- 2021-02-12 PH PH1/2022/552099A patent/PH12022552099A1/en unknown
- 2021-02-12 WO PCT/US2021/017799 patent/WO2021163438A1/en not_active Ceased
- 2021-02-12 CA CA3167318A patent/CA3167318A1/en active Pending
- 2021-02-12 KR KR1020227031351A patent/KR20220142472A/ko active Pending
- 2021-02-12 AU AU2021221139A patent/AU2021221139A1/en active Pending
- 2021-02-12 BR BR112022016220A patent/BR112022016220A2/pt unknown
- 2021-02-12 PE PE2022001743A patent/PE20230301A1/es unknown
- 2021-02-12 US US17/760,174 patent/US20240277831A1/en active Pending
-
2022
- 2022-08-16 CO CONC2022/0011467A patent/CO2022011467A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4103230A1 (en) | 2022-12-21 |
| PE20230301A1 (es) | 2023-02-13 |
| WO2021163438A1 (en) | 2021-08-19 |
| MX2022009860A (es) | 2022-11-07 |
| KR20220142472A (ko) | 2022-10-21 |
| BR112022016220A2 (pt) | 2022-10-25 |
| JP2023513720A (ja) | 2023-04-03 |
| JP7897796B2 (ja) | 2026-07-30 |
| PH12022552099A1 (en) | 2024-01-29 |
| CA3167318A1 (en) | 2021-08-19 |
| CN116096404A (zh) | 2023-05-09 |
| US20240277831A1 (en) | 2024-08-22 |
| AU2021221139A1 (en) | 2022-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022016220A2 (pt) | Polipeptídeos, composições e seu uso para tratar ou limitar o desenvolvimento de uma infecção | |
| BR112018004642A2 (pt) | processo para tratamento capilar | |
| ES2721898T3 (es) | Formulaciones estables para liofilizar partículas terapéuticas | |
| DE602006021547D1 (de) | Zusammensetzungen und methoden zur topischen anwendung und zur transdermalen verabreichung eines oligopeptids | |
| CO2022009532A2 (es) | Nuevas composiciones de ácido modificado | |
| PE20130588A1 (es) | Hepcidina, antagonistas de la hepcidina y metodos de uso | |
| BR112012033091A2 (pt) | método de cimentação, e, composição de cimento | |
| AR016368A1 (es) | Agentes tensoactivos de sulfonato de alquilbenceno mejorados | |
| MX2019013982A (es) | Construccion de expresion viral que comprende una secuencia codificadora del factor de crecimiento de fibroblastos 21 (fgf21). | |
| MX2024000901A (es) | Composiciones y metodos para la degradacion selectiva de proteinas dise?adas por ingenieria. | |
| CL2012000683A1 (es) | Composicion refrescante para reducir el mal olor que comprende 0,01 a 0,07% de polimero para mal olor que comprende polietilenimina homopolimerica; neutralizador del mal olor que comprende aldehido alifatico; un portador acuoso; en donde la composicion esta libre de material que ensucia o mancha telas; y metodo para reducir el mal olor. | |
| AR125379A1 (es) | Un fab anti-tslp con estabilidad mejorada | |
| AR062556A1 (es) | Composiciones farmaceuticas de clonazepam y metodos de uso de las mismas | |
| BRPI0509521A (pt) | composições de pana de dpa alquiladas | |
| BR112021006288A2 (pt) | composição terapêutica, e, métodos para tratar um paciente e para tratar câncer. | |
| JOP20220353A1 (ar) | آلية إطلاق عطر، وطريقة لها واستخداماتها | |
| ATE447929T1 (de) | Selbstbräuner enthaltend wasserlösliche vitamin b3-komponente und bräunungswirkstoff mit alpha- hydroxycarbonyl-gruppierung | |
| CO6592079A2 (es) | Solución acuosa de polímero peine metacrílico fluido con un extracto seco superios a 60% proceso de fabircación y uso como agente fluidificante | |
| AR070177A1 (es) | COMPOSICIONES BACTERIANAS QUE COMPRENDEN PROTEíNAS PERTENECIENTES AL GRUPO DE RECEPTORES DE RECONOCIMIENTO DE PATRONES (PRR) QUE PRESENTAN UN DOMINIO DE REPETICIoN DE LEUCINA (RRL) | |
| MX2024001301A (es) | Anticuerpos y conjugados de anticuerpo especificos para nectina 4 y metodos de uso de los mismos. | |
| ES2124865T3 (es) | Dispersiones acuosas de ceras y siliconas, su obtencion y empleo. | |
| CL2022002214A1 (es) | Polipéptidos, composiciones y su uso para tratar o limitar el desarrollo de una infección | |
| AR129864A1 (es) | Péptidos y métodos para uso en tratar el dolor | |
| MX2013008955A (es) | Nuevos peptidos implicados en la treyectoria de señale scf c-kit y composiciones que los contienen. | |
| BRPI0410655A (pt) | composição farmacêutica, método de tratar ou prevenir uma infecção pelo vìrus da raiva em um indivìduo em necessidade deste tratamento, vetor de expressão de rhabdovìrus recombinante, célula hospedeira de mamìfero, método de produzir uma anticorpo recombinante humano neutralizante do vìrus da raiva em uma célula de mamìfero, e, uso de uma combinação |